The US Food and Drug Administration (FDA) on Monday finalized guidance to pharmaceutical and biotech sponsors looking for more advice on when non-inferiority studies demonstrating effectiveness of an ...
The European Medicines Agency (EMA) is proposing a new guideline on sponsors’ use of non-inferiority designs to assess the safety and effectiveness of new drugs in clinical trials. The proposal aims ...
Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results